FindTrial
Sign In

MVT-5873

DRUG5 trials

Sponsors

BioNTech Research & Development, Inc., National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center

Conditions

CholangiocarcinomaColon CancerLiver MetastasisMetastatic Colon CarcinomaPancreatic CancerPancreatic CarcinomaTumors That Express CA 19-9Tumors That Express CA19-9

Phase 1

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
TerminatedNCT02672917
BioNTech Research & Development, Inc.Pancreatic Cancer
Start: 2016-01-31End: 2025-01-14Updated: 2025-01-28
Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1
TerminatedNCT02687230
BioNTech Research & Development, Inc.Pancreatic Carcinoma, Tumors That Express CA19-9
Start: 2016-07-11End: 2017-05-05Updated: 2021-08-31
Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy
TerminatedNCT03118349
BioNTech Research & Development, Inc.Pancreatic Carcinoma, Tumors That Express CA 19-9
Start: 2017-06-01End: 2018-04-11Updated: 2023-04-21
Study of a New Technique for Imaging Pancreatic Cancer
CompletedNCT04883775
Memorial Sloan Kettering Cancer CenterPancreatic Cancer, Tumors That Express CA19-9
Start: 2021-05-10End: 2025-01-27Updated: 2025-01-30

Phase 2

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
CompletedNCT03801915
National Cancer Institute (NCI)Cholangiocarcinoma, Colon Cancer, Liver Metastasis +2
Start: 2019-11-13End: 2022-05-27Updated: 2023-03-21

Related Papers

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.
Journal of Clinical Oncology2024-01-201 citations
Perioperative MVT-5873, a fully human monoclonal antibody against a CA 19-9 epitope, for operable CA 19-9 producing pancreatic cancers, cholangiocarcinomas, and metastatic colorectal cancers.
Journal of Clinical Oncology2020-05-201 citations
Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer
Journal of Gastrointestinal Oncology2020-04-0116 citations
Abstract I18: Retooling a blood-based biomarker into a theranostic agent
Cancer Research2019-12-13
Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
2018-10-0118 citations
HuMab-5B1 (MVT-5873), a mAb targeting sLe<sup>a</sup>, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.
Journal of Clinical Oncology2018-05-206 citations
Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe<sup>a</sup>, in patients with pancreatic cancer and other CA19-9 positive malignancies.
Journal of Clinical Oncology2017-05-204 citations
Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model
Cancer Research2016-12-144 citations